Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Truscreen Group (TRU) / HY22

Operating cash burn widened to NZ$1.7m as cash fell to NZ$3.7m

Reported loss narrowed in dollar terms but operating cash outflow grew, drawing cash down 17.8% and total equity 13.4% over the period.

Healthcare / Medical diagnostics

TRU revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY26 was $2.4m, versus $0.74m in HY23.

TRU EBITDA margin

EBITDA margin across covered periods.

↗
Loading chart...
FY26 was -90.4%, versus -164.9% in HY23.

TRU operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY26 was -$2.5m, versus -$1.2m in HY23.

TRU working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY26 was $0.9m, versus $0.2m in HY23.
Release date
29 November 2021
Published
23 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY22 vs HY21

Revenue

$0.75m

+24.8% ↑ vs $0.6m

Net profit after tax

−$1.3m

+13.3% ↑ vs −$1.5m

Net cash inflow from operating activities

−$1.7m

-9.3% ↓ vs −$1.6m

Declared dividend per share

0.0c

— vs —

Profit before tax

−$1.3m

+13.3% ↑ vs −$1.5m

Cash and cash equivalents

$3.7m

-17.8% ↓ vs $4.5m

Total assets

$10.3m

-15.0% ↓ vs $12.2m

What changed

TruScreen's operating cash outflow widened to NZ$1.7m from NZ$1.6m in the prior comparable half, even as the absolute statutory loss reduced from NZ$1.5m to NZ$1.3m

Because the prior comparable revenue base was affected by IFRS 15 timing on a Zimbabwe shipment, the reported revenue, PBT and NPAT growth percentages carry a basis-discontinuity caveat and should not be read as clean like-for-like rates.

Cash and equivalents fell to NZ$3.7m from NZ$4.5m, a NZ$0.8m draw in six months. Borrowings of NZ$0.4m were fully repaid to zero, and total equity declined 13.4% to NZ$9.7m, consistent with the period loss and no new capital.

Trade receivables collapsed to NZ$7k from NZ$0.2m, while inventories rose 13.3% to NZ$0.7m.

What matters

Cash runway is the central economic question

Against the NZ$3.7m balance, the half-year operating outflow of NZ$1.7m implies roughly twelve to fourteen months of cover at the current burn rate before a further capital event is required. Capex was zero versus NZ$0.1m last year, so the cash consumption is essentially operating, not investment-related.

Working capital signals warrant attention. Trade debtors essentially zeroed out while inventory built — receivable days fell from 47.9 to 1.7 while inventory days remained elevated at 169. Combined with the small revenue base, this points to lumpy, cash-on-shipment customer behaviour rather than a stable receivables book, and to stock held against expected but not yet contracted orders.

The commercial story remains forward-leaning. Management cites 35% growth in Single Use Sensor unit sales, first sales into Eastern Europe, and an anticipated private Health Check placement under the SWXT relationship. These are leading indicators rather than realised earnings drivers; the financial statements still show a sub-scale business well short of operating breakeven.

Expectations

No stated forward target or guidance is provided in the release, and no forward-work disclosure is available

The FY21 reference point reflects a different statutory magnitude and does not produce a meaningful second-half shape signal for this period.

What the result does support is that revenue is growing off a small base and unit volumes are scaling. What it does not support is a near-term path to operating cash breakeven, nor does it address when commercial milestones in Vietnam, Mexico, Eastern Europe or the SWXT partnership translate to a revenue level capable of covering current operating costs.

Quality of result

The narrowing of the absolute loss does not translate to cash

Operating cash outflow worsened by NZ$0.1m year on year, so cash conversion deteriorated against the prior comparable half. The reported revenue and loss improvements should be read against a prior comparable base that included the IFRS 15 timing effect on a Zimbabwe shipment, which is why the headline growth percentages have been flagged with a basis-discontinuity caveat and not cited as specific rates here.

Repayment of NZ$0.4m of borrowings to zero strengthens the legal balance sheet but consumed cash that the operating business cannot currently replenish. Inventory build to NZ$0.7m carries forward to future periods as either fulfilled orders or written-down stock; at the current revenue run-rate that is roughly a year of sales sitting on the balance sheet.

In substance, the durable signal is volume growth in Single Use Sensors. The less durable signals are the receivables collapse to near zero and the absolute loss reduction, both of which reflect period-end timing more than a step change in operating economics.

Unresolved

Open questions

What is the expected timing and source of the next capital event, given approximately twelve to fourteen months of cover at the current burn rate?
Why did trade receivables fall to almost zero, and does this reflect a shift to upfront-payment terms or simply shipment timing around 30 September?
How quickly does management expect the Eastern Europe, Vietnam and SWXT private Health Check opportunities to convert from commentary into invoiced revenue?
What gross margin does Single Use Sensor volume carry, and at what unit run-rate does the business cover its fixed cost base?
Will the company continue to operate without borrowings, or is non-equity funding being considered to extend runway?

This briefing cannot assess management's specific commercial pipeline, contract values, or the probability that announced channel partners translate to revenue in any defined timeframe.

Chat

Ask about TRU HY22

Ask follow-up questions about Truscreen Group's HY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about TRU HY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Truscreen Group's HY22 result.

What is the expected timing and source of the next capital event, given approximately twelve to fourteen months of cover at the current burn rate?Why does "Cash runway is the central economic question" matter?How strong was the cash and earnings quality in HY22?What should I watch next for TRU after HY22?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

TruScreen Half Year Report September 2021

HY22 / financial report↗

TruScreen Results Announcement Template September 2021

HY22 / results announcement↗

TruScreen September 2021 Results Announcement

HY22 / results release↗

Prior comparable period

TruScreen Half Year Results Announcement 30 September 2020

HY21 / results release↗

TruScreen Results Template 30 September 2020

HY21 / results announcement↗

TruScreen Unaudited Interim Condensed Financial Statements 30 September 2020

HY21 / financial report↗

Full-year context

Financial Results Announcement March 2021

FY21 / results announcement↗

Financial Results Announcement March 2021

FY21 / results release↗

Truscreen Preliminary Final Report March 2021

FY21 / financial report↗

Release context

Annual Shareholder Meeting Presentation

HY22 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Revenue growth context

Revenue growth was 24.8% for this reporting period.

→

Working-capital pressure

Inventory days were 169 days, -17 days versus the prior comparable period.

→

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.0pp.

→

ROE and capital efficiency

ROE was -13.0%, +0.5pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when TRU publishes next

Get the next Truscreen Group briefing and related NZX reporting-season updates by email.